A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25 C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

The present invention refers to a composition comprising eriodictyol and guaifenesin. In particular, the present invention refers to a composition comprising criodictyol and guaifenesin, said composition being for medical use, in particular for use in the prevention and treatment of respiratory diseases. Moreover, the present invention relates to the use of eriodictyol and guaifenesin for the preparation of a pharmaceutical composition. Finally. the present invention relates to the use of eriodictyol for masking or inhibiting the bitter taste of guaifenesin or guaifenesin comprising compositions.

The present invention relates to the field of traditional Chinese medicine formulation, particularly to a composition and the preparation method and use thereof. The traditional Chinese medicine composition provided by the present invention is produced from raw materials comprising TARAXACI HERBA, GLYCYRRHIZAE RADIX ET RHIZOMA, PLATYCODONIS RADIX, CITRI RETICULATAE PERICARPIUNM and PHYLLANTHI FRUCTUS. The traditional Chinese medicine composition adopts fewer herb medicines. By reasonable combination, the various herbal medicines mutually reinforce in terms of the effects of clearing throat, anti-inflammation and reducing phlegm, exhibit obvious synergistic effect. Pharmacological tests and clinical trials indicate that the traditional Chinese medicine composition has significant throat clear, anti-inflammatory, expectorant effects (p<0.05), and has no obvious toxic and side effects.

The present invention is directed to novel compounds of formula I ##STR00001##
and their use as therapeutic compounds.

According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in regenerating ascorbate systemically and thus in the therapeutic treatment of chronic obstructive pulmonary disease.

The invention relates to respirable dry particles that contain one or more divalent metal cations, such as magnesium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.

Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.

The present invention relates to cough syrups containing ambroxol hydrochloride, characterised in that they are substantially free from glycerol, and their use for mucolytic treatment in acute and chronic diseases of the bronchi and/or lungs.

A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25 C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.